Viewing entries in


View Post →

Letter Addressing FTC Settlement

Nov 1, 2019

We recently settled a Federal Trade Commission (FTC) inquiry into practices by our company and our partner Neora International, LLC. Signum was offered a settlement where we would pay no money,.

View Post →

New Publication for SIG-1273™ and AGE IQ™

Dec 3, 2018

Excited to announce that our latest research for SIG-1273™ and AgeIQ™ has been published in the Journal of Cosmetic Dermatology. We demonstrate that SIG-1273™ has anti-pollution properties and.

View Post →

A new article was released this Friday on the effects of SIG-1459

Jun 13, 2018

Gizmodo released an article last Friday on SIG-1459 following up on the anti-acne story after the release of the New Scientist article earlier that week. We are so happy to see such a big response to.

View Post →

New articles on the effects of Signum's new compound SIG-1459 on acne

Jun 11, 2018

Last week we had two big articles written on the effects of our new compound SIG-1459 on acne, and we couldn't be more excited!

View Post →

New anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™

May 16, 2018

Signum presented new anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™  at the International Investigative Dermatology Conference March 16-19 in Orlando, Florida. This conference.

View Post →

Signum's novel new molecular entities hold Significant pharmaceutical potential

Apr 30, 2017

We presented at this years Society of Investigative Dermatology Conference held in Portland, Oregon. The annual meeting covers not only basic science, but also emergent clinical and translational.

View Post →

Signum Attending BIO International Convention on June 18-22, 2017

Apr 20, 2017

Signum Biosciences, INC. will be attending this years BIO International Convention in San Diego, California.

View Post →

Signum Biosciences awarded best poster at the 3rd annual DDRI Conference.

Mar 1, 2017

Dr. Jose Fernandez represented Signum Biosciences at this years DDRI Conference.  He presented a poster"From Consumer Products to Drugs: Developing Novel Technologies in Dermatology and Neurology" .

View Post →

View Post →

SIG-990 aka ( DMT210) has entered into a Phase 2 Acne Rosacea Study conducted by our Dermata Therapeutics, LLC

Jan 31, 2017

Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the.

Subscribe Here!